Andrew W. Lo

Dr. Andrew W. Lo co-founded QLS Advisors in 2019 and currently serves as the firm’s Chairman and Co-CIO. He is also the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of MIT’s Laboratory for Financial Engineering, and principal investigator at MIT’s Computer Science and Artificial Intelligence Laboratory. Prior to QLS, Dr. Lo was Chairman and Chief Investment Strategist of AlphaSimplex Group, a quantitative investment company.  His healthcare-related research interests include new financial and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and predicting clinical trial outcomes via machine learning techniques. Dr. Lo is a co-founder of BridegBio Pharma, Quantile Health, and Uncommon Cures; a director of AbCellera, Atomwise, BridgeBio Pharma, and Vesalius; and an advisor to the American Cancer Society’s BrightEdge Impact Fund. He holds a B.A. in economics from Yale University and an A.M. and Ph.D. in economics from Harvard University.